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Objectives Our aim was to identify shortcomings in the management of patients with both atrial fibrillation (AF) and heart
failure (HF).
Background AF and HF often coincide in cardiology practice, and they are known to worsen each other’s prognosis, but little
is known about the quality of care of this combination.
Methods In the observational Euro Heart Survey on AF, 5,333 AF patients were enrolled in 182 centers across 35 Euro-
pean Society of Cardiology member countries in 2003 and 2004. A follow-up survey was performed after 1 year.
Results At baseline, 1,816 patients (34%) had HF. Recommended therapy for HF with left ventricular systolic dysfunction
(LVSD) with a beta-blocker and either an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II recep-
tor blocker was prescribed in 40% of HF patients, while 29% received the recommended drug therapy for both
LVSD-HF and AF, consisting of the combination of a beta-blocker, either ACEI or angiotensin II receptor blocker,
and oral anticoagulation. Rate control was insufficient with 40% of all HF patients with permanent AF having a
heart rate 80 beats/min. In the total cohort, HF patients had a higher risk for mortality (9.5% vs. 3.3%; p 
0.001), (progression of) HF (24.8% vs. 5.0%; p  0.001), and AF progression (35% vs. 19%; p  0.001) during
1-year follow-up. Of all recommended drugs for AF and LVSD-HF, only ACEI prescription was associated with im-
proved survival during 1-year follow-up (odds ratio: 0.51 [95% confidence interval: 0.31 to 0.85]; p  0.011).
Conclusions The prescription rate of guideline-recommended drug therapy for AF and LVSD-HF is low. Randomized controlled
trials targeting this highly prevalent subgroup with AF and HF are warranted. (J Am Coll Cardiol 2009;53:
1690–8) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.055T
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atrial fibrillation (AF) and heart failure (HF) often co-exist.
he Framingham Heart study showed that in a general
opulation of 50 years, the incidence of HF among AF
atients was 33 in 1,000 patient-years, and the incidence of
F among HF patients was 54 in 1,000 patient-years (1).
rom the *Department of Cardiology, University Hospital Maastricht, Maastricht,
he Netherlands; †Department of Cardiology, University of Hull, Castle Hill
ospital, Kingston upon Hull, United Kingdom; ‡Section of Medical Cardiology and
xercise Medicine, Glasgow Royal Infirmary University NHS Trust, Glasgow,
nited Kingdom; §Department of Cardiology, University Hospital of Heraklion,
rete, Greece; Department of Cardiology, Guglielmo da Saliceto Hospital, Pia-
enza, Italy; ¶Department of Cardiology, Hospital Universitario Gregorio Maranon,
adrid, Spain; #Department of Cardiology, VieCuri Medical Center, Venlo, the
etherlands; and the **AMC, Heart Failure Research Centre, University of Amster- ahe Euro Heart Surveys of current cardiology practice in
atients with AF or with HF showed that HF is present in
4% of AF patients, and AF in 42% of HF patients (2,3).
oth HF (4) and AF (5) alone are associated with an
ncrease in mortality, and when these pathologies coincide,
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May 5, 2009:1690–8 AF and HF Managementortality is even higher (1). The development of AF is
ikely to cause worsening of HF and greatly complicates
anagement. Worsening of HF is also likely to provoke the
nset of AF. AF and worsening HF constitute a classic
vicious circle’ of deterioration in HF.
Separate guidelines exist for the management of AF and
F, both with paragraphs on their combined management
hat differ in their recommendations (6–8). This may add
onfusion to what is already a complex situation. Little
nformation is available regarding the combined manage-
ent of AF and HF in clinical practice. For these reasons,
e investigated guideline adherence regarding drug therapy
hen both AF and HF were encountered in the Euro Heart
urvey on AF. In addition, we investigated the impact of
F and its management on the management, progression,
nd prognosis of AF patients during 1-year follow-up.
ethods
urvey methods, center participation, patient characteristics,
anagement, and definitions of the baseline and follow-up
urvey of the Euro Heart Survey on AF have previously been
escribed (2,9). In summary, 5,333 ambulant and hospital-
zed patients with AF were enrolled in cardiology practices
f 182 hospitals among 35 countries in 2003 to 2004.
atients were enrolled if they were 18 years of age and if
hey had an electrocardiogram or Holter recording showing
F during the qualifying admission/consultation or in the
receding 12 months. A follow-up was performed to assess
ortality and incidence of major adverse events during 1
ear.
efinitions. The previous publications on the general re-
ults of the baseline and follow-up surveys of the Euro
eart Survey on AF contain definitions of variables re-
orted here (2,9). Definitions of variables specific for this
aper are listed in the following text.
HF: the presence of signs and symptoms of either right
elevated central venous pressure, hepatomegaly, dependent
dema) or left ventricular failure (exertional dyspnea, cough,
atigue, orthopnea, paroxysmal nocturnal dyspnea, cardiac
nlargement, rales, gallop rhythm, pulmonary venous con-
estion) or both, confirmed by noninvasive or invasive
easurements demonstrating objective evidence of cardiac
ysfunction.
Heart failure with left ventricular systolic dysfunction
LVSD-HF): a clinical diagnosis of HF in combination
ith echocardiographic study within the preceding year
howing left ventricular ejection fraction 45% (8).
Heart failure with preserved left ventricular systolic func-
ion (PSF-HF): a clinical diagnosis of HF in combination
ith echocardiographic left ventricular ejection fraction
45% (8).
Recommended drug therapy: according to both the Eu-
opean Society of Cardiology and American College of Car-
iology/American Heart Association 2001 guidelines on HF
10,11), valid during the recruitment period of the survey, the oombination of a beta-blocker and
n angiotensin-converting enzyme
nhibitor (ACEI) or angiotensin II
eceptor blocker (ARB) was con-
idered to be “recommended drug
herapy for LVSD-HF.” Guide-
ines for both AF (12) and HF
11) also recommended use of oral
nticoagulants (OAC) in patients
ith HF and AF. Therefore, a
ombination of beta-blocker,
CEI, or ARB and OAC at dis-
harge or end of visit was defined
s “recommended drug treatment
or LVSD-HF and AF” and we
ill also refer to this as “the full
ackage.” There is less evidence
f the efficacy of these drugs in
SF-HF.
Contraindications for recom-
ended drug therapy: for “rec-
mmended drug therapy for
VSD-HF,” we took into ac-
ount the following potential
ontraindications: ventricular rate 50 beats/min, renal
ailure, chronic obstructive pulmonary disease (COPD),
ick sinus syndrome, systolic blood pressure 85 mm Hg,
nd atrioventricular block grade 2 to 3. For the full package
f “recommended therapy for AF and LVSD-HF” the same
ontraindications were used, with the addition of major
leeding and malignancy as potential contraindications for
AC. All these contraindications are also applicable to
SF-HF patient and were only taken in account for analysis
hen explicitly stated in the text.
Rate control drugs: drug therapy at discharge or end of
isit with beta-blockers, digoxin, digitoxin, diltiazem, vera-
amil, and also amiodarone and sotalol, since these 2 drugs
ave rate control properties.
CHADS2 score: stroke risk score, calculated by adding 1
oint for each of the following conditions: congestive HF,
ypertension, age 75 years or diabetes, and 2 points for
rior stroke or transient ischemic attack (13).
tatistical analysis. Data analysis was performed with
PSS statistical software (version 12.01, SPSS Inc., Chi-
ago, Illinois). Continuous variables are reported as mean
SD), or with a skewed distribution as median (25th to
5th percentile), and categorical variables as observed num-
er (percentage). Differences were tested with indepen-
ent t test for continuous variables with normal distribu-
ion, Mann-Whitney for continuous variables with
kewed distribution, and with chi-square statistic for
ategorical variables.
Multivariable logistic regression was performed to iden-
ify patient characteristics that were associated with a lower
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
AF  atrial fibrillation
ARB  angiotensin II
receptor blocker
CAD  coronary artery
disease
CI  confidence interval
COPD  chronic
obstructive pulmonary
disease
HF  heart failure
LVSD  left ventricular
systolic dysfunction
NYHA  New York Heart
Association
OAC  oral anticoagulation
OR  odds ratio
PSF  preserved systolic
functionr higher likelihood to receive appropriate drug therapy
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AF and HF Management May 5, 2009:1690–8mong HF patients. In these analyses we incorporated the
ollowing covariates: age, sex, body mass index, systolic
lood pressure at baseline, ventricular rate at baseline,
oronary artery disease (CAD), valvular heart disease, hy-
ertension, hyperlipidemia, diabetes, prior stroke/transient
schemic attack, prior other thromboembolism, prior major
leeding, AF type, renal failure, prior malignancy, periph-
ral vascular disease, COPD, AF symptoms, prior minor
leeding, sick sinus syndrome, hyperthyroidism, prior ven-
ricular fibrillation, prior ventricular tachycardia, atrioven-
ricular block grade 2 to 3, sinus rhythm at end of visit, New
ork Heart Association (NYHA) functional class, and type
f HF (LVSD-HF vs. PSF-HF) only when being the
entral issue. Further, we performed multivariable logistic
egression to assess the independent effect of HF, type of
F, and appropriate drug therapy on mortality during
-year follow-up. In these analyses we incorporated the
ame covariates as mentioned in the prior text, with the
ollowing additional covariates: rate or rhythm control,
ntiplatelet drug, dihydropyridin calcium-channel blocker,
tatin, and also the individual drugs OAC, ACEI, ARB,
nd beta-blocker, or their combination as “appropriate
herapy” as needed depending on the central issue. Diuretics
ere kept out of the models because it represented a
urrogate of HF severity and masked the effect of HF and
YHA functional class on outcomes due to this colinearity.
The effect of individual drugs on outcomes might be
iased by the absence of randomization, and therefore a
ropensity score for each drug was added to multivariable
odels in order to correct as well as possible for the
ropensity of a physician to select patients for the concern-
ng drug. Individual propensity scores were calculated by
eans of backward deletion logistic regression (see meth-
dology in the next paragraph). The propensity scores for all
rugs were added as continuous variables to the multivari-
ble logistic regression analyses. Propensity scores were kept
n the model regardless of their significance until the
ssociated drug was deleted.
For all multivariable logistic regression analyses, variables
ere removed stepwise from the model when the p value
xceeded 0.10. Variables with p values 0.05 in the final
odel were considered to be significant contributors and
ere kept in the model. Hereafter, all variables in the final
odels were tested for interactions and significant interac-
ions were added to the models. These models were vali-
ated by means of bootstrapping, which was performed with
00 samples for each multivariable logistic regression anal-
sis. Bootstrapping provided information on the effect
tability of each factor and interaction as a predictor of the
utcome variable. Effects that were unstable were stepwise
eft out of the model, which eventually resulted in the final
odel with only stable significant effects. The final models
re reported here, with the net odds ratio (OR), 95%
onfidence interval (CI), and p value. results
mong 5,333 patients in the Euro Heart Survey on AF,
,816 patients (34%) had HF, 3,482 (66%) did not, and for
5 patients (0.66%) HF status was unknown.
atient characteristics. AF patients with HF were older
nd had more comorbidities than AF patients without HF
Table 1). As a consequence, HF patients were far more
ften categorized in CHADS2 stroke risk score 2 or higher
Fig. 1). Most patients having AF and HF (74%) were in
YHA functional class II or III.
Among 1,088 HF patients with recent echocardiographic
nformation, 42% had a decreased and 58% preserved left
entricular systolic function. AF patients with LVSD-HF
ere younger and more often had a history of CAD,
specially myocardial infarction, and had a larger left atrial
ize (Table 1). Patients with PSF-HF were more likely to be
omen and to have associated conditions, mainly mitral
tenosis or valve surgery, and hypertension.
anagement of patients with AF and HF. Chest X-ray
nd transthoracic echocardiography were more likely and
nterventions to restore sinus rhythm less likely to be per-
ormed in HF patients (Table 2). Digitalis, beta-blockers,
iuretics, OAC, and ACEIs were more often prescribed in
atients with HF. In patients with LVSD-HF, diuretics,
miodarone, and digitalis use was higher than in PSF-HF,
hile no difference was found for ACEI, ARB, beta-blocker,
erapamil, diltiazem, aspirin, or OAC (Table 2).
Among patients having both AF and HF, drug therapy for
VSD-HF was given in 40% (Fig. 2), which changed only
arginally to 44% after exclusion of 595 patients with potential
ontraindications for a beta-blocker, ACEI, or ARB (see the
ethods section). Recommended LVSD-HF drug prescrip-
ion was similar in LVSD-HF and PSF-HF patients (45% vs.
1%; p  0.218) (Fig. 2), also after exclusion of potential
ontraindications (50% vs. 48%; p  0.745). No effect of HF
ype on prescription on recommended therapy was observed in
ultivariable analysis.
The full package of recommended drug therapy for
VSD-HF and AF was given in 29% of the 1,816 patients
ith AF and HF (Fig. 2), which increased slightly to 32%
fter exclusion of 673 patients with potential contraindica-
ions for recommended therapy for LVSD-HF and AF.
omen (OR: 0.65 [95% CI: 0.51 to 0.82]; p  0.001) and
atients with COPD (OR: 0.43 [95% CI: 0.31 to 0.59];
 0.001), sinus rhythm at discharge (OR: 0.63 [95% CI:
.47 to 0.84]; p  0.001), or high systolic blood pressure at
aseline (OR: 0.99 per 1 mm Hg increase [95% CI: 0.99 to
.00]; p  0.018) were less likely to receive this optimal
reatment among all HF patients, while patients with CAD
OR: 1.37 [95% CI: 1.08 to 1.73]; p  0.010), hyperlipid-
mia (OR: 1.49 [95% CI: 1.17 to 1.90]; p  0.001),
iabetes (OR: 1.31 [95% CI: 1.00 to 1.70]; p  0.048), and
rst detected AF as compared with paroxysmal and perma-
ent AF (overall p  0.001) had a higher chance for
eceiving recommended therapy. Prescription of the full
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May 5, 2009:1690–8 AF and HF Managementackage was higher in LVSD-HF than in PSF-HF patients
35% vs. 28%; p 0.014) (Fig. 2), which was nonsignificant
fter exclusion of patients with potential contraindications
aseline Characteristics of AF Patients With Versus Without HF an
Table 1 Baseline Characteristics of AF Patients With Versus W
No HF (n  3,482) HF (n  1,81
Enrollment characteristics
Enrolled at outpatient clinic 39 23
Enrolled at university hospital 45 52
AF only reason for visit 54 15
Demographics
Age, yrs 66 13 69 12
Women 41 44
Body mass index, kg/m2 28 8 28 6
Cardiac history
Valvular heart disease 20 40
Mitral stenosis or valve surgery 8 17
Coronary artery disease 27 45
Myocardial infarction 12 25
Angina pectoris 16 27
PCI 6 7
CABG 6 8
Congenital heart disease 2 2
Sick sinus syndrome 4 6
Ventricular tachycardia 2 5
Ventricular fibrillation 1 2
Pacemaker implantation 5 8
ICD 1 2
Catheter ablation 3 2
Other pathologies
Hypertension 62 67
Diabetes 15 24
COPD 10 20
Malignancy 5 6
Peripheral vascular disease 6 11
Renal failure 3 10
Stroke/transient ischemic attack 9 13
Clinical characteristics
AF type
First detected 21 14
Paroxysmal 34 20
Persistent 22 23
Permanent 23 43
Electrocardiogram
Ventricular rate, beats/min 91 31 94 29
QRS duration, mm 96 25 105 33
QT interval, mm 369 59 377 141
Left ventricular hypertrophy 14 31
Echocardiogram
Left atrial size, mm 44 8 49 9
LVEF, % 55 13 47 15
LVESD, mm 35 7 42 10
LVEDD, mm 51 7 56 9
esults are reported as % or mean  SD.
AF atrial fibrillation; CABG  coronary artery bypass grafting; COPD  chronic obstructive pulm
nd-diastolic diameter; LVEF left ventricular ejection fraction; LVESD left ventricular end-systoli
ntervention; PSF-HF  heart failure with preserved left ventricular systolic function.38% vs. 32%; p  0.126). No significant effect of HF type tn this appropriate drug prescription was observed in
ultivariable analysis.
The combination of a beta-blocker and digitalis was given
SD-HF Versus PSF-HF
t HF and LVSD-HF Versus PSF-HF
p Value LVSD-HF (n  455) PSF-HF (n  633) p Value
0.001 15 17 0.594
0.001 78 75 0.394
0.001 13 13 0.801
0.001 65 12 67 12 0.009
0.047 30 51 0.001
0.025 28 8 28 5 0.302
0.001 38 41 0.280
0.001 12 17 0.016
0.001 51 39 0.001
0.001 27 16 0.001
0.001 28 26 0.541
0.253 7 4 0.055
0.001 8 4 0.006
0.989 2 1 0.479
0.004 6 5 0.272
0.001 6 4 0.054
0.001 2 2 0.984
0.001 7 5 0.181
0.001 4 1 0.001
0.001 2 1 0.384
0.001 62 73 0.001
0.001 25 23 0.513
0.001 21 18 0.272
0.393 4 5 0.534
0.001 10 8 0.320
0.001 8 7 0.449
0.001 12 9 0.118
0.001 16 16 0.602
18 21
23 24
43 40
0.001 98 29 92 28 0.002
0.001 108 35 100 30 0.001
0.002 375 61 368 61 0.066
0.001 37 34 0.331
0.001 50 9 47 10 0.001
0.001 32 8 57 9 0.001
0.001 50 9 35 7 0.001
0.001 60 9 54 8 0.001
disease; HF  heart failure; ICD  implantable cardioverter-defibrillator; LVEDD  left ventricular
ter; LVSD-HF heart failure with left ventricular systolic dysfunction; PCI percutaneous coronaryd LV
ithou
6)
onary
c diameo 20% of all HF patients, and 40% received any combina-
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AF and HF Management May 5, 2009:1690–8ion of rate control drugs. These prescription rates were
imilar in HF patients with permanent AF, 24% and 38%,
espectively, while 16% did not receive any rate control
rugs. Only 40% of patients with HF and permanent AF
ad a resting heart rate 80 beats/min at baseline. Patients
ith LVSD-HF were more likely to receive multiple rate
ontrol drugs than those with PSF-HF (50% vs. 37%; p 
.001).
HF patients with an ACEI/ARB more often received a
eta-blocker (46% vs. 37%; p  0.001) and also OAC (69%
s. 63%; p  0.013) than patients without an ACEI/ARB.
n the same manner, patients with a beta-blocker more
ften received OAC (72% vs. 63%; p  0.001).
dverse events, disease progression, and treatment dur-
ng 1-year follow-up. During 1-year follow-up, AF pa-
ients with HF had a substantially worse outcome than
hose without HF in univariable analysis, and also a higher
ardiovascular and all-cause mortality after correction for
ifferences in baseline characteristics in multivariable anal-
sis (Table 3).
Among HF patients, old age, prior major bleeding, prior
troke or transient ischemic attack, and low systolic blood
ressure at baseline were significantly associated with a
igher all-cause mortality (Table 4). However, being in
inus rhythm at discharge, female sex, and ACEI use were
ssociated with a lower mortality. No effect was found of
F type with regard to mortality. Receipt of recommended
rug therapy for LVSD-HF and also for AF and
VSD-HF combined was not associated with a better
utcome among all HF patients, nor in patients with
SVD-HF or PSF-HF.
AF was more likely to progress during 1 year in patients
ith HF (35% vs. 19%; p  0.001), but progression was
imilar in those with LVSD-HF and PSF-HF (both 35%;
Figure 1 Distribution of the CHADS2 Stroke Risk Score
in Patients With Versus Without Heart Failure
See the Methods section for definition of CHADS2 stroke risk score. 0.947). Among patients with a first episode of AF and cithout HF at baseline, 7% were diagnosed with HF in the
ollowing year.
iscussion
his analysis of the Euro Heart Survey on AF provides a
nique and comprehensive overview of patient characteris-
ics, treatment, and outcome of patients who have both HF
nd AF. Our analysis confirms that patients with combined
F and HF have a grim prognosis with a 1-year mortality
f 9.5% and worsening of HF in almost 25%. These patients
ight be severely undertreated, with regard to drug therapy
or stroke prevention, HF therapy, and rate control.
troke risk in HF and AF. The 2001 HF and AF
uidelines (10–12) recommended OAC in all AF patients
ith HF. In contrast, 32% of our population did not receive
AC, and this could not be fully explained by the presence
f potential contraindications. A previous analysis of the
uro Heart Survey on AF also showed that OAC therapy
as hardly tailored to the CHADS2 score and that patients
ith HF were not more likely to receive OAC than other
atients with AF (14). The 2006 AF guidelines—which
onsider LVSD-HF to be at higher risk than PSF-HF—
nly recommend OAC in HF patients when there is at least
other CHADS2 stroke risk factor present (6). Neverthe-
ess, using the 2006 criteria, still 94% of all HF patients
hould have received OAC in our survey. In addition, the
% of HF patients who exclusively had HF as a risk factor
re likely to develop another risk factor in time. Therefore
he straightforward recommendation to routinely prescribe
AC to all patients with AF and HF might improve
ppropriate OAC application in this patient group.
ombined management of HF and AF. In HF patients,
ess diagnostic testing like thyroid function or exercise tests,
n order to find a cause for AF, had been performed. It
eems that with the combined presentation of AF and HF
reciprocal cause for both diseases is assumed, and no
urther diagnostic testing is deemed necessary. This is in
ontrast to the AF guidelines, which recommend intense
creening for pathologic causes.
In HF, both ARBs and ACEIs reduce morbidity and
ortality and are therefore recommended by the HF guide-
ines. Also, both drugs have the potential to decrease atrial
ressure, reduce (atrial) fibrosis and AF recurrence (15–17).
t is therefore encouraging to see that ACEI prescription
as higher in the HF group. Beta-blockers are also recom-
ended in patients with LVSD-HF, but only 50% actually
eceived this drug. The combination of either an ACEI or
RB with a beta-blocker (“recommended drug therapy for
VSD-HF”) was prescribed in only 44% of patients with
F and AF who did not have potential contraindications.
igitalis should be added to a beta-blocker for rate control
n patients with LVSD-HF and AF. However, 78% of
atients with LVSD-HF did not receive this combination,
nd only one-half of the patients received more than 1 rate
ontrol drug. Considering the fact that few of these patients
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May 5, 2009:1690–8 AF and HF Managementad a ventricular rate below 80 beats/min, rate control was
robably inadequate.
Taking into account the fact that OAC was highly
ecommended in all patients with AF and HF by the 2001
F guidelines, only 32% of patients without contraindica-
ions received the full package of ACEI/ARB, beta-blocker,
nd OAC. These individual drugs tended to cluster within
atients, which might indicate general unawareness of
ecommended therapy in specific physicians, but possibly
lso clustering of contraindications for multiple drugs in
atients, or the requirement of extra reinforcement by the
resence of another comorbidity requiring the same drugs.
eciprocal impact of HF and AF, and the effect of drug
herapy. In agreement with previous observational results,
e showed that HF dramatically worsens prognosis of AF
atients (1). Having sinus rhythm at discharge (even though
ssociated with low adherence to HF and AF treatment)
anagement of AF Patients With Versus Without HF and LSVD-HF
Table 2 Management of AF Patients With Versus Without HF a
No HF (n  3,482) HF (n  1,8
Diagnostics*
Chest X-ray 77 89
Transthoracic echocardiogram 81 90
Transesophageal echocardiogram 14 11
Holter monitoring 28 31
Event recorder 2 1
Exercise test 23 17
Electrophysiology 6 5
Thyroid hormone 50 41
Interventions†
Pharmacological cardioversion 24 17
Electrical cardioversion 19 14
Catheter ablation 4 1
Pacemaker 4 4
ICD 0 1
Rate/rhythm control drugs
Class I antiarrhythmic 13 4
Amiodarone 23 27
Sotalol 9 2
Digitalis 19 43
Diltiazem 4 4
Verapamil 5 5
Beta-blocker‡ 40 50
Antithrombotic drugs
Oral anticoagulation 63 68
Antiplatelet drug 32 33
Heparin 5 7
None 10 6
Other drugs
ACEI 42 64
ARB 13 12
ACEI/ARB 54 75
Diuretic 36 82
Dihydropyridin CCB 14 10
Statin 26 24
esults are reported as %. *Performed at the time of the survey or at any time prior to inclusion;
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin II receptor blocker; CCB nd receiving an ACEI was associated with a lower risk for sll-cause mortality, but no difference in mortality was found
etween a rate and rhythm control strategy. Probably sinus
hythm simply reflects a better hemodynamic cardiac situ-
tion and might therefore be an independent prognostic
arker rather than a treatment target. In contrast to ACEI,
he effect of beta-blockers on mortality in patients with HF
nd AF is not yet established in a prospective manner and
ur results add doubt since no protective effect was found
uring 1-year follow-up. Interestingly, very few studies
ddressing the effect of beta-blockers in HF patients having
F have been published. Carvedilol is the only beta-blocker
ith a proven protective effect in this specific population,
lthough solely based on 1 small prospective randomized
rial (18). Larger prospective randomized trials assessing the
ffect of carvedilol and other beta-blockers in patients with
oth HF and AF are needed to asses whether or not a
eta-blocker is favorable. Until then, it is recommended to
s PSF-HF
VD-HF Versus PSF-HF
p Value LVSD-HF (n  455) PSF-HF (n  633) p Value
0.001 93 86 0.001
0.001 100 100 1.000
0.004 13 9 0.072
0.049 31 32 0.868
0.006 2 1 0.659
0.001 16 13 0.134
0.053 6 4 0.096
0.001 38 38 0.925
0.001 20 18 0.356
0.001 15 12 0.072
0.001 1 1 0.497
0.219 4 3 0.813
0.001 2 1 0.351
0.001 2 5 0.057
0.001 34 28 0.038
0.001 1 1 0.538
0.001 51 38 0.001
0.429 6 4 0.368
0.991 4 5 0.196
0.001 53 49 0.313
0.001 66 66 0.839
0.155 33 37 0.216
0.002 11 6 0.001
0.001 10 5 0.002
0.001 71 67 0.202
0.157 12 11 0.690
0.001 81 78 0.200
0.001 86 78 0.001
0.001 9 11 0.232
0.121 24 21 0.232
med at the time of the survey or planned thereafter; ‡excluding sotalol.
-channel blocker; NS  not significant; other abbreviations as in Table 1.Versu
nd LS
16)tart a beta-blocker in patients with HF and AF. The low
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AF and HF Management May 5, 2009:1690–8troke rates with lack of differences between groups might
ndicate that the actual risk of stroke is comparable in
atients with HF versus without HF and LVSD-HF versus
SF-HF, or that OAC is more effective in the groups with
resumed higher stroke risk (HF and LVSD-HF). Either
ay, the high OAC application rate in combination with
he low rate of stroke and also bleeding points towards an
ncreasing the appropriate use of antithrombotic treatment,
lthough 1 of 3 patients was still undertreated.
Patients with AF and HF had evidence of substantial left
entricular and left atrial structural remodeling compared
ith patients without HF. In addition, they had more
dvanced forms of AF, were more likely to progress to
ersistent and permanent AF, and were less likely to
ndergo cardioversion. This reinforces the notion that HF
nd AF are part of a vicious circle of deterioration but also
uggests that this complex disease combination may instill a
ense of therapeutic futility and nihilism among clinicians
hat adversely affects the management of both conditions.
ndeed, only 32% of patients without potential contraindi-
Figure 2 Application Rates of Recommended
Drug Therapy in Patients With AF and HF
See the Methods section for recommended drug therapy for LVSD-HF and for
LVSD-HF and atrial fibrillation (AF). HF  heart failure; LVSD-HF  heart failure
with left ventricular systolic dysfunction; PSF-HF  heart failure with preserved
left ventricular systolic function.
nivariable and Multivariable Effect of HF on Mortality and Adverse
Table 3 Univariable and Multivariable Effect of HF on Mortality
Univariable
HF No HF
All-cause mortality 127 (9.5%) 93 (3.3%)
Cardiovascular mortality 71 (5.5%) 26 (0.9%)
Stroke 20 (1.6%) 43 (1.6%)
Any thromboembolism 48 (3.8%) 70 (2.6%)
Major bleeding 34 (2.7%) 34 (1.3%)
HF 314 (24.7%) 135 (5.0%)
esults for the univariable analyses are reported as observed number of events (%). *Effect of HF a
rocedures as mentioned in the Methods section. The reported insignificant multivariable results concern
CI  confidence interval; OR  odds ratio; other abbreviations as in Table 1.ations received combined treatment with OAC, beta-
lockers, and ACEIs or ARBs suggesting a large shortfall in
he quality of care.
VSD-HF versus PSF-HF. Our findings that PSF-HF
atients were older, more often women, and more fre-
uently had a history of hypertension, and that LVSD-HF
atients more often had a history of vascular disease, are in
ine with previous reports (19,20).
In the 2005 HF guidelines no treatment recommendation
s given for PSF-HF other than treating associated diseases
ike hypertension (7,8). Adding to this their high morbidity
nd mortality and our findings that only few receive recom-
ended therapy for LVSD-HF stresses the importance for
urther research on the optimal treatment of HF patients
ith PSF. It is remarkable though that we did not find a
ifference between LVSD-HF and PSF-HF for the appli-
ation of recommended drugs for LVSD-HF. This might
ndicate that left ventricular function does not play a major
ole in the decision to apply recommended therapy in
atients with AF and HF. However, the high presence of
ther pathologies in PSF-HF warranting the same
rugs—as shown by the positive association of diabetes with
rescription of recommended drugs—might mask an actual
igher application rate due to left ventricular dysfunction in
VSD-HF. Nevertheless, the application rates of recom-
ended drugs in LVSD-HF were low and warrant inves-
igation of the reasons for undertreatment of this HF group
ith the strongest evidence base.
nts in AF Patients
Adverse Events in AF Patients
Multivariable*
p Value OR 95% CI p Value
0.001 2.40 1.71–3.36 0.001
0.001 4.32 2.53–7.37 0.001
0.952 0.77 0.40–1.49 0.441
0.043 0.97 0.52–1.81 0.929
0.001 1.55 0.88–2.73 0.132
0.001 4.69 3.60–6.12 0.001
ared with the reference group without HF, corrected for covariates according to the model building
ultivariable Determinants ofll-Cause Mortality in Pa ients With AF and HF
Table 4 Multivariable Determinants ofAll-Cause Mortality in Patients With AF and HF
Risk Factor
Odds Ratio
(95% CI) p Value
Age, per yr increase 1.06 (1.04–1.08) 0.001
Sinus rhythm at discharge 0.37 (0.21–0.64) 0.001
Major bleeding 4.15 (1.98–8.69) 0.001
Systolic blood pressure, per mm Hg increase 0.98 (0.97–0.99) 0.001
Stroke/TIA 2.01 (1.22–3.32) 0.009
ACE inhibitor 0.51 (0.31–0.85) 0.011
Female sex 0.61 (0.40–0.95) 0.027
CE  angiotensin-converting enzyme; CI  confidence interval; TIA  transient ischemic attack;
ther abbreviations as in Table 1.Eve
and
s comp
effects of HF one step before HF was eliminated from the model.
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May 5, 2009:1690–8 AF and HF ManagementNo differences in major adverse events between PSF-HF
nd LVSD-HF were observed. One explanation for the
isparity between clinical trials and surveys is that the higher
ardiovascular mortality associated with LVSD-HF is offset
y a higher noncardiovascular mortality in PSF-HF
ssociated with the higher rate of comorbidities in this
opulation. Furthermore, in patients with PSF-HF, AF
ight worsen outcome even more than in LVSD-HF
atients (21).
tudy limitations. Patients with AF and HF were more
ften lost to follow-up after 1 year (25% vs. 18%; p 0.001)
nd we might have underestimated mortality and incidence
f adverse events in this group, compared with patients with
olely AF. In 37% of HF patients we could not determine
ype of HF (LVSD-HF or PSF-HF) due to the absence of
ecent echocardiography data. We have not been able to
xtract all potential contraindications for recommended
rug therapy, like periodic bradycardia, hyperkalemia,
hronic liver disease, and refusal of therapy. Further, the
alues for the potential contraindications ventricular rate
nd systolic blood pressure in this survey were snapshots and
ight have been different in the past. Therefore, we cannot
ssess whether different values in the past were reason for
ot prescribing beta-blockers. We did not have information
n drug dosages and since dosing of recommended drugs in
aily practice is frequently lower than proven effective in
rials, this might partially explain the absence of efficacy of
ome drugs in our survey. A mere 36% of AF patients
ithout HF were using diuretics. In this patient group,
iagnosis of HF is frequently overlooked (22), leading to a
igher event rate in the presumed solely AF group. There
as no clear widespread consensus for the exact diagnosis of
F at the time of designing the survey, which might make
ur definition of HF prone to discussion. Nevertheless, we
imed to assess adequacy of treatment of patients with AF
nd HF, and once the physician considered the patients in
ur survey to have both pathologies they should treat them
s such. Finally, 50% of the population was enrolled in
niversity hospitals, which usually see more severely dis-
ased patients than other hospitals, but are often well
nformed on evidence-based medicine, and recommended
herapy application rates might even be lower in other
ettings.
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